<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=896170837107954&amp;ev=PageView&amp;noscript=1">

Teleflex Announces 200,000 Patients Treated with UroLift System for Enlarged Prostate

Minimally Invasive, Same-Day Outpatient Procedure Provides Rapid Symptom Relief and Recovery

Read More

Teleflex Announces Positive Data Emphasizing the Effectiveness of the UroLift® System Treatment for Enlarged Prostate Across Broad Patient Populations

Data Presented at European Association of Urology Highlights Safety and Versatility of the Minimally Invasive UroLift System in a Real-World Setting

Read More

Teleflex Announces Publication of Early Patient Experience Data Highlighting the UroLift® System as a Superior Treatment to Rezum™ Steam Injection in Patients with Enlarged Prostate

Data Shows Minimally Invasive Treatment Provides Rapid Symptom Relief, Allowing Men to Return to Daily Activities Quickly

Read More

In Honor of Men’s Health Month, Teleflex Announces Virtual Community Health Talk for Men with Benign Prostatic Hyperplasia

Free, Online Presentation to Address Symptoms of Enlarged Prostate, Treatment Options and Tips for Managing Condition During Pandemic

WAYNE, PA.— June 8, 2020—Teleflex Incorporated (NYSE: TFX) today announced that the company will host a free community health talk to discuss the symptoms, diagnosis and treatment options for enlarged prostate, also known as Benign Prostatic Hyperplasia (BPH). Dr. Wayne Kuang* will lead the webinar which can be viewed live on Wednesday, June 17 at 8:00 a.m. PDT and again at 4:30 p.m. PDT. Men and / or their partners from anywhere in the U.S. can attend the event.

BPH is a non-cancerous enlargement of the prostate that occurs as men age. This common condition is marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep and decreased quality of life.1 If left untreated, the condition can worsen over time and cause permanent bladder damage.2

“We are excited to offer our first ever virtual community health talk – a result of our efforts to stay connected with our patient community during the current pandemic,” said Dave Amerson, president of Teleflex Interventional Urology business unit. “Maintaining health is top of mind for many of us as we continue to navigate life in the midst of a pandemic. Our aim is to share information about BPH to a broad audience so that men who may be suffering from symptoms have accurate and reliable information they need to make informed decisions for their health.”

“As providers, we are dedicated to empowering our patients to get the information they need to make informed decisions about their health during this unprecedented time,” said Dr. Wayne Kuang, MD For Men, Albuquerque, NM. “Our goal for this timely webinar during Men’s Health Month is to provide attendees with a better understanding of how to address the challenges of an enlarged prostate – a condition that affects more than 40 million men in the U.S. alone3,4– and provide information about treatment solutions, such as the UroLift® System, for those experiencing BPH symptoms.”

Register to participate in this informative webinar by following this link: www.UroLift.com/seminar.

About the UroLift System
The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function.**3,4 Patients also experienced significant improvement in quality of life. Over 175,000 men have been treated with the UroLift System worldwide.*** Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in many markets worldwide. Learn more at www.UroLift.com.

About Teleflex Interventional Urology
The Teleflex Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving sexual function.**4,5 Learn more at www.NeoTract.com.

About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.Teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose.

Read More

Teleflex Announces Positive Data Showing that the UroLift® System Effectively Relieves Enlarged Prostate Symptoms While Preserving Patients’ Sexual Function*

Data Presented at American Urological Association 2020 Virtual Experience Highlight Benefits and Superior Sexual Function* Preservation of the Minimally Invasive Treatment for Patients with Enlarged Prostate

Read More

Teleflex Celebrates 175,000 Patients Treated with the UroLift® System

Minimally Invasive Treatment for Enlarged Prostate Provides Rapid Relief1 and Durable Results2

WAYNE, Pa.— March 11, 2020—Teleflex Incorporated (NYSE: TFX) today announced that 175,000 patients have now been treated globally* with its minimally invasive UroLift® System—a safe and effective treatment for Benign Prostatic Hyperplasia (BPH) that provides rapid symptom relief and improved quality of life, while preserving sexual function.**1,3

BPH, also known as enlarged prostate, is a non-cancerous enlargement of the prostate that occurs as men age. This common condition is marked by bothersome urinary symptoms, such as getting up frequently at night to urinate, that can lead to loss of productivity, depression, and decreased quality of life.4 BPH affects over 40 million men in the United States alone.5 If left untreated, the condition can worsen over time and cause permanent bladder damage.6

Read More

Teleflex Announces FDA Clearance for Expanded Indication of the UroLift® System for Treatment of Larger Prostates, Up to 100cc

Minimally Invasive Procedure Now Available to Hundreds of Thousands More Men with Enlarged Prostate, Providing Safe and Effective Symptom Relief.

Read More

Teleflex Announces Urology Times Article Highlighting the UroLift System as Providing a Superior Patient Experience for Treating Enlarged Prostate

Minimally Invasive Treatment Options for BPH Remain Critical Due to Shortcomings of Surgery and Medication

Read More

Teleflex Announces Publication of a Large Real-World Study Confirming Results from Controlled Clinical Studies of the UroLift® System

Results from Multi-Center Study Support the Application of Minimally Invasive Treatment for Broader BPH Population

Read More

Teleflex Announces Expanded Nationwide Coverage for the UroLift System for Patients with Enlarged Prostate

Coverage Decision by Anthem Increases Access to Minimally Invasive Treatment, Offering Patients Rapid, Durable Symptom Relief

Read More